Mammographic density to predict response to neoadjuvant systemic breast cancer therapy

[1] Cain H(2017)Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice Clin Oncol (r Coll Radiol) 29 642-652

[2] Macpherson IR(2014)Association between mammographic features and response to neoadjuvant chemotherapy in locally advanced breast carcinoma Hematol Oncol Stem Cell Ther 7 149-156

[3] Beresford M(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-172

[4] Pinder SE(2019)The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay Breast Cancer Res Treat 177 67-75

[5] Pong J(2015)Mammographic breast density: predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients Breast 24 576-581

[6] Dixon JM(1951)Note on exact treatment of contingency, goodness of fit and other problems of significance Biometrika 38 141-149

[7] Castaneda CA(2010)American Society of Clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784-2795

[8] Flores R(2015)High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium Breast Cancer Res 17 79-S77

[9] Rojas K(2015)Neoadjuvant treatment of breast cancer–Clinical and research perspective Breast 24 S73-1792

[10] Flores C(2014)Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes Breast Cancer Res 16 R65-1169

[1] Cain H(2017)Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice Clin Oncol (r Coll Radiol) 29 642-652

[2] Macpherson IR(2014)Association between mammographic features and response to neoadjuvant chemotherapy in locally advanced breast carcinoma Hematol Oncol Stem Cell Ther 7 149-156

[3] Beresford M(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-172

[4] Pinder SE(2019)The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay Breast Cancer Res Treat 177 67-75

[5] Pong J(2015)Mammographic breast density: predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients Breast 24 576-581

[6] Dixon JM(1951)Note on exact treatment of contingency, goodness of fit and other problems of significance Biometrika 38 141-149

[7] Castaneda CA(2010)American Society of Clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784-2795

[8] Flores R(2015)High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium Breast Cancer Res 17 79-S77

[9] Rojas K(2015)Neoadjuvant treatment of breast cancer–Clinical and research perspective Breast 24 S73-1792

[10] Flores C(2014)Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes Breast Cancer Res 16 R65-1169